Microvasculopathy and soft tissue calcification in mice are governed by fetuin-A, magnesium and pyrophosphate.

Anne Babler,Juergen Floege,Carlo Schmitz,Willi Jahnen-Dechent,Andrea Buescher,Theo Gorgels,Felix Gremse,Marietta Herrmann,Elena Aikawa

doi:10.1371/journal.pone.0228938

Abstract

Calcifications can disrupt organ function in the cardiovascular system and the kidney, and are particularly common in patients with chronic kidney disease (CKD). Fetuin-A deficient mice maintained against the genetic background DBA/2 exhibit particularly severe soft tissue calcifications, while fetuin-A deficient C57BL/6 mice remain healthy. We employed molecular genetic analysis to identify risk factors of calcification in fetuin-A deficient mice. We sought to identify pharmaceutical therapeutic targets that could be influenced by dietary of parenteral supplementation. We studied the progeny of an intercross of fetuin-A deficient DBA/2 and C57BL/6 mice to identify candidate risk genes involved in calcification. We determined that a hypomorphic mutation of the Abcc6 gene, a liver ATP transporter supplying systemic pyrophosphate, and failure to regulate the Trpm6 magnesium transporter in kidney were associated with severity of calcification. Calcification prone fetuin-A deficient mice were alternatively treated with parenteral administration of fetuin-A dietary magnesium supplementation, phosphate restriction, or by or parenteral pyrophosphate. All treatments markedly reduced soft tissue calcification, demonstrated by computed tomography, histology and tissue calcium measurement. We show that pathological ectopic calcification in fetuin-A deficient DBA/2 mice is caused by a compound deficiency of three major extracellular and systemic inhibitors of calcification, namely fetuin-A, magnesium, and pyrophosphate. All three of these are individually known to contribute to stabilize protein-mineral complexes and thus inhibit mineral precipitation from extracellular fluid. We show for the first time a compound triple deficiency that can be treated by simple dietary or parenteral supplementation. This is of special importance in patients with advanced CKD, who commonly exhibit reduced serum fetuin-A, magnesium and pyrophosphate levels.

Highlights

Pathological calcifications, the gradual deposition of calcium phosphate salts [1] in tissue not physiologically meant to mineralize are frequent and are mostly considered benign
We performed computed tomography (CT) and calcified lesion volume rendering in wildtype and fetuin-A deficient DBA/2 and C57BL/6 mice
Fetuin-A is a potent systemic regulator of ectopic calcification mediating the solubilization and clearance of circulating protein-mineral complexes, which might otherwise cause calcification [28, 29]. In this present study parenteral supplementation of fetuin-A inhibited the formation of ectopic calcifications in a fetuin-A deficient mouse model

Summary

Introduction

Pathological calcifications, the gradual deposition of calcium phosphate salts [1] in tissue not physiologically meant to mineralize are frequent and are mostly considered benign. In particular in the context of chronic kidney disease (CKD), vascular calcifications have increasingly been recognized as a major contributor to cardiovascular morbidity and mortality independent of traditional risk factors [2]. Calcifications start in the extracellular matrix by nucleation of calcium phosphate crystals in the absence of mineralization regulators [5], before any osteogenic reprograming of resident or invading mesenchymal cells occurs [6, 7]. Phosphate retention in CKD is a major driver of vascular calcification, endothelial damage, and the cardiovascular morbidity and mortality associated with CKD [5]. Dietary and blood phosphate reduction are prime targets of renal replacement therapy

Methods

Results

Conclusion